NA

Naturalendo Tech Co., Ltd

Biotech R&D of natural ingredients for health and wellness solutions.

168330 | KO

Overview

Corporate Details

ISIN(s):
KR7168330009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 판교로 255 번길 58, 에이동 301호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Naturalendo Tech Co., Ltd. is a biotechnology company specializing in biosciences, herbs, and endocrinology. The company engages in the research, development, manufacturing, and sale of hormone biotechnology products, biological agents, and food additives. It focuses on developing health and beauty solutions derived from natural ingredients. The company's core activities revolve around the R&D and commercialization of new functional materials for the health and wellness sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-05-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.1 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-12 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 83.1 KB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 104.4 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.9 KB
2025-03-31 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.6 KB
2025-03-31 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.4 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 17.4 KB
2025-03-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.9 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.8 KB
2025-03-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB

Automate Your Workflow. Get a real-time feed of all Naturalendo Tech Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Naturalendo Tech Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Naturalendo Tech Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Phoenix Asia Holdings Ltd Logo
A subcontractor for substructure projects and a large-scale manufacturer of fine chemicals & APIs.
United States of America
PHOE
Photocure ASA Logo
Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.
Norway
PHO
Pierrel Logo
Global pharma company specializing in dental anesthetics and contract manufacturing services.
Italy
PRL
PLIANT THERAPEUTICS, INC. Logo
Developing novel integrin-based therapies for fibrosis and related diseases.
United States of America
PLRX
Develops DNA vaccines and therapeutics for companion animals and livestock.
South Korea
222670
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel
PLUR
PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America
PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America
PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea
041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG

Talk to a Data Expert

Have a question? We'll get back to you promptly.